Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Chest

• Publication date

  2004-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1378/CHEST.125.3.965PMID 15006955
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Maintaining Fluoroquinolone Class Efficacy: Review of Influencing Factors

  2003cited by this paper
• Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000.

  2002cited by this paper
• Surveillance of resistance in bacteria causing community-acquired respiratory tract infections.

  2002cited by this paper
• Levofloxacin Penetration into Epithelial Lining Fluid as Determined by Population Pharmacokinetic Modeling and Monte Carlo Simulation

  2002cited by this paper
• Pharmacokinetics of Intravenous and Oral Levofloxacin in Critically Ill Adults in a Medical Intensive Care Unit

  2002cited by this paper
• The in vivo-in vitro paradox in pneumococcal respiratory tract infections.

  2002cited by this paper
• Clinical and economic implications of antimicrobial resistance for the management of community-acquired respiratory tract infections.

  2002cited by this paper
• Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects.

  2001cited by this paper
• Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents.

  2001cited by this paper
• Pharmacodynamics of Fluoroquinolones againstStreptococcus pneumoniae in Patients with Community-Acquired Respiratory Tract Infections

  2001cited by this paper
• The challenge of prescribing treatment for respiratory tract infections.

  2000cited by this paper
• The challenge of prescribing treatment for respiratory tract infections.

  2000cited by this paper
• Pharmcokinetics and Pharmacodynamics of the Fluoroquinolones

  2000cited by this paper
• Pharmacodynamic Comparisons of Levofloxacin, Ciprofloxacin, and Ampicillin against Streptococcus pneumoniae in an In Vitro Model of Infection

  1999cited by this paper
• Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia.

  1999cited by this paper
• Concentrations of gatifloxacin in plasma and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy.

  1999cited by this paper
• Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy.

  1999cited by this paper
• Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

  1998cited by this paper
• Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials.

  1998cited by this paper
• Expanding indications for the new macrolides, azalides, and streptogramins.

  1997cited by this paper
• Concentrations of levofloxacin (HR 355) in the respiratory tract following a single oral dose in patients undergoing fibre-optic bronchoscopy.

  1997cited by this paper
• Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers

  1997cited by this paper
• Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects

  1996cited by this paper
• Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin

  1996cited by this paper
• Pulmonary disposition of antimicrobial agents: methodological considerations

  1992cited by this paper
• Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution.

  1986cited by this paper
• Antibiotic uptake by alveolar macrophages.

  1980cited by this paper

• Modeling lung transporters and their influence on inhaled drug disposition.

  2025cites this paper
• A Review on the Role of Moxifloxacin in the Treatment and Management of Respiratory Tract Infections

  2025cites this paper
• Bronchopulmonary disposition of IV cefepime/taniborbactam (2–0.5 g) administered over 2 h in healthy adult subjects

  2023cites this paper
• Develop adult extrapolation to pediatrics and pediatric dose optimization based on the physiological pharmacokinetic model of azithromycin

  2023influential citation
• Intracellular Accumulation of Novel and Clinically Used TB Drugs Potentiates Intracellular Synergy

  2021cites this paper
• Antimicrobial Treatment and Prophylaxis of Plague: Recommendations for Naturally Acquired Infections and Bioterrorism Response

  2021cites this paper
• Pharmacokinetics and pharmacodynamics of levofloxacin in bronchial mucosa and lung tissue of patients undergoing pulmonary operation.

  2020cites this paper
• Azithromycin in viral infections

  2020cites this paper
• Moxifloxacin in Chronic Obstructive Pulmonary Disease: Pharmacokinetics and Penetration into Bronchial Secretions in Ward and Intensive Care Unit Patients

  2019cites this paper
• Role of Microbiome in Lung Injury

  2019cites this paper
• Low penetrance of antibiotics in the epithelial lining fluid. Experience from the use of inhaled antibiotics in patients with non CF-bronchiectasis.

  2019cites this paper
• In Vitro Activity of Levonadifloxacin (WCK 771) against Chlamydia pneumoniae

  2019cites this paper
• Intrapulmonary Pharmacokinetics of Lascufloxacin in Healthy Adult Volunteers

  2018cites this paper
• Intracellular Pharmacokinetics of Antibacterials and Their Clinical Implications

  2018influential citation
• In Vitro Activities of the Benzoquinolizine Fluoroquinolone Levonadifloxacin (WCK 771) and Other Antimicrobial Agents against Mycoplasmas and Ureaplasmas in Humans, Including Isolates with Defined Resistance Mechanisms

  2018cites this paper
• Macrolide maintenance treatment for bronchiectasis

  2017cites this paper
• Strategies to improve treatment of nontuberculous mycobacterial disease

  2017cites this paper
• University of Groningen Macrolide maintenance treatment for bronchiectasis

  2017cites this paper
• Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach

  2017cites this paper
• Penetration of Ciprofloxacin and Amikacin into the Alveolar Epithelial Lining Fluid of Rats with Pulmonary Fibrosis

  2017cites this paper
• Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens.

  2016cites this paper
• Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo

  2016cites this paper
• Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.

  2016cites this paper
• Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease

  2016cites this paper
• To attach or not to attach : factors behind variable adhesion properties of cryopreserved human hepatocytes

  2016cites this paper
• Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid.

  2016cites this paper
• Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients.

  2015cites this paper
• Rapid Drug Tolerance and Dramatic Sterilizing Effect of Moxifloxacin Monotherapy in a Novel Hollow-Fiber Model of Intracellular Mycobacterium kansasii Disease

  2015cites this paper
• Update on a proper use of systemic fluoroquinolones in adult patients (ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin, pefloxacin. SPILF.).

  2015cites this paper
• β-lactam antibiotic pharmacokinetics during continuous venovenous haemofiltration in critically ill patients: continuous infusion versus intermittent bolus administration

  2015influential citation
• Phase I, Open-Label, Safety and Pharmacokinetic Study To Assess Bronchopulmonary Disposition of Intravenous Eravacycline in Healthy Men and Women

  2014cites this paper
• Gender Analysis of Moxifloxacin Clinical Trials

  2014cites this paper
• Antimycobacterial Drugs Modulate Immunopathogenic Matrix Metalloproteinases in a Cellular Model of Pulmonary Tuberculosis

  2014cites this paper
• Pharmacokinetics and Pharmacodynamics of Aerosolized Antibacterial Agents in Chronically Infected Cystic Fibrosis Patients

  2014cites this paper
• Intravenous Azithromycin in Preterm Infants at Risk for Ureaplasma Respiratory 2 Colonization 3 Running Title : Azithromycin 20 mg / kg multi-dose in preterm infants 4

  2014cites this paper
• Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats: 1. Ciprofloxacin, Moxifloxacin, and Grepafloxacin

  2014cites this paper
• Voriconazole in Lung Transplant Recipients Epithelial Lining Fluid Concentrations of Relationship between Trough Plasma and

  2014cites this paper
• Antibiotic therapy of infectious exacerbations of COPD: a place of levofloxacin

  2014cites this paper
• Pharmacokinetics, Microbial Response, and Pulmonary Outcomes of Multidose Intravenous Azithromycin in Preterm Infants at Risk for Ureaplasma Respiratory Colonization

  2014cites this paper
• Intrapulmonary concentration of levofloxacin in patients with idiopathic pulmonary fibrosis.

  2014cites this paper
• Population pharmacokinetics of intravenous levofloxacin 500 mg/day dosage in infected patients.

  2014cites this paper
• Preserving the efficacy of front-line fluoroquinolones through selective use to optimise clinical outcomes.

  2014cites this paper
• Gewebepenetration von Antibiotika

  2014cites this paper
• Salvage therapy for multidrug-resistant tuberculosis.

  2014cites this paper
• Relationship between Trough Plasma and Epithelial Lining Fluid Concentrations of Voriconazole in Lung Transplant Recipients

  2013cites this paper
• Defining Antibiotic Dosing in Lung Infections

  2013cites this paper
• Microdialysis in Antibiotic Research

  2013cites this paper
• Methods to measure target site penetration of antibiotics in critically ill patients.

  2013cites this paper
• Rothia mucilaginosa Pneumonia Diagnosed by Quantitative Cultures and Intracellular Organisms of Bronchoalveolar Lavage in a Lymphoma Patient

  2013cites this paper
• Evaluation of Combinations of 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine with Clinically Used Antiretroviral Drugs

  2013cites this paper
• Aerosolised levofloxacin in cystic fibrosis

  2013cites this paper
• Évaluation biopharmaceutique des antibiotiques pour le traitement des infections pulmonaires

  2012cites this paper
• Summary of Pharmacokinetics and Tissue Distribution of a Broad‐Spectrum Fluoroquinolone, JNJ‐Q2

  2012cites this paper
• Pulmonary Disposition of Tedizolid following Administration of Once-Daily Oral 200-Milligram Tedizolid Phosphate in Healthy Adult Volunteers

  2012cites this paper
• Levofloxacin

  2012cites this paper
• Macrolides inhibit cytokine production by alveolar macrophages in bronchiolitis obliterans organizing pneumonia.

  2012cites this paper
• Parámetros farmacodinámicos y farmacocinéticos de las fluoroquinolonas respiratorias. Guía para la selección de la fluoroquinolona más apropiada

  2012cites this paper
• [Pharmacodynamic and pharmacokinetic evaluation of respiratory fluoroquinolones. Guideline to selection of the most appropriate fluoroquinolone].

  2012cites this paper
• Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750 mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis.

  2012cites this paper
• Chapter 6 – Prenatal and Postnatal Microbial Colonization and Respiratory Outcome in Preterm Infants

  2012cites this paper
• Comparing therapeutic and adverse effects of moxifloxacin and levofloxacin in treatment of community acquired pneumonia: A meta-analysis of randomized controlled trials

  2012influential citation
• Levofloxacin for the treatment of respiratory tract infections

  2012cites this paper
• Characterization of the active efflux of fluoroquinolones in eukaryotic cells

  2012influential citation
• Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a pharmacokinetic/pharmacodynamic model of uninfected and infected macrophages.

  2011cites this paper
• Pharmacokinetics, Safety, and Biologic Effects of Azithromycin in Extremely Preterm Infants at Risk for Ureaplasma Colonization and Bronchopulmonary Dysplasia

  2011cites this paper
• Penetration of Anti-Infective Agents into Pulmonary Epithelial Lining Fluid

  2011influential citation
• Modulation of Biofilm of Strains Isolated from Patients with Chronic Obstructive Pulmonary Disease by Levofloxacin, Moxifloxacin, Ciprofloxacin, Amoxicillin/Clavulanic Acid and Ceftriaxone

  2011cites this paper
• Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis: a pharmacokinetic and pharmacodynamic approach.

  2011cites this paper
• Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis

  2011cites this paper
• Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity : studies with gemifloxacin , moxifloxacin and ciprofloxacin in a pharmacokinetic / pharmacodynamic model of uninfected and infected macrophages

  2011cites this paper
• Strategies to Address Appropriate Fluoroquinolone Use in the Hospital

  2010cites this paper
• Determination of critical concentrations of second-line anti-tuberculosis drugs with clinical and microbiological relevance.

  2010cites this paper
• Ureaplasma species: role in diseases of prematurity.

  2010cites this paper
• Levofloxacin in the treatment of community-acquired pneumonia

  2010cites this paper
• Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap!

  2010cites this paper
• Antibiotics in acute exacerbations of chronic bronchitis

  2010cites this paper
• Antibiotika-Konzentration im Serum und in Bronchialepithel-Flüssigkeit unter kontinuierlicher Infusion

  2010cites this paper
• Permeability and Concentration of Levofloxacin in Epithelial Lining Fluid in Patients With Lower Respiratory Tract Infections

  2010cites this paper
• Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis.

  2010cites this paper
• In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations

  2010cites this paper
• Fluoroquinolones in the management of community-acquired pneumonia in primary care

  2010cites this paper
• Fluoroquinolones in the management of community‐acquired pneumonia

  2010cites this paper
• Bronchopulmonary Disposition of Intravenous Voriconazole and Anidulafungin Given in Combination to Healthy Adults

  2009cites this paper
• COMMUNITY-ACQUIRED PNEUMONIA

  2009cites this paper
• In vitro selection of resistance in Streptococcus pneumoniae at in vivo fluoroquinolone concentrations.

  2009cites this paper
• 10 years’ experience with the pneumococcal quinolone moxifloxacin

  2009cites this paper
• Anti-inflammatory effects of antibacterials on human bronchial epithelial cells

  2009influential citation
• [PK/PD profile and post-marketing surveillance of levofloxacin].

  2009cites this paper
• Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China

  2009cites this paper
• Pharmacokinetics of azithromycin in serum, bronchial washings, alveolar macrophages and lung tissue following a single oral dose of extended or immediate release formulations of azithromycin.

  2008cites this paper
• Bronchopulmonary Disposition of Micafungin in Healthy Adult Volunteers

  2008cites this paper
• Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease.

  2007cites this paper
• Bronchoalveolar Lavage as a Research Tool

  2007cites this paper
• Interpretation of Antibiotic Concentration Ratios Measured in Epithelial Lining Fluid

  2007cites this paper
• MINIREVIEW Interpretation of Antibiotic Concentration Ratios Measured in Epithelial Lining Fluid (cid:1)

  2007cites this paper
• A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP)

  2007influential citation
• Antibacterial Effects of Moxifloxacin and Levofloxacin Simulating Epithelial Lining Fluid Concentrations gainst Community-Acquired Methicillin-Resistant

  2007cites this paper
• Tissue penetration of antibacterial agents: how should this be incorporated into pharmacodynamic analyses?

  2007cites this paper
• brief review of moxi fl oxacin in the treatment of elderly patients with community-acquired pneumonia ( CAP )

  2007cites this paper
• Optimizing use of quinolones in the critically ill.

  2007cites this paper